0_1218 To fully halt the pandemic spread of the virus, in addition to preventive measures, it is necessary to implement frontline and widely accessible treatment strategies. The PACECOR* project is actively developing a novel treatment method to battle SARS-CoV-2 infection with a mode of action that is indifferent to the virus's mutations. The NANO-CNR team, using in-silico and in vitro methodologies, is currently active in the design and experimental validation of an antiviral strategy based on a product capable of highly selectively inhibiting the binding of the Spike protein of the SARS-CoV-2 virus and its variants to cell receptors, preventing the virus from entering target cells. Some preliminary results of in vitro experiments on the ACE2 targeting effectiveness of selected compounds will be presented. *PRIN 2020 - COD.2020LW7XWH - LS1 - PACECOR - "EARL Y PHASE PRECLINICAL DEVELOPMENT OF P ACECOR, A MUTATION-INDEPENDENT ANTI-SARS-CO2 THERAPEUTIC STRATEGY" funded by Ministero dell’Università e della Ricerca , Italy (CUP:B53C20040400006)